These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 21623279)

  • 1. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
    Johnson ML; Riely GJ; Rizvi NA; Azzoli CG; Kris MG; Sima CS; Ginsberg MS; Pao W; Miller VA
    J Thorac Oncol; 2011 Jun; 6(6):1128-31. PubMed ID: 21623279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
    Chaft JE; Oxnard GR; Sima CS; Kris MG; Miller VA; Riely GJ
    Clin Cancer Res; 2011 Oct; 17(19):6298-303. PubMed ID: 21856766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
    Wheler J; Falchook G; Tsimberidou AM; Hong D; Naing A; Piha-Paul S; Chen SS; Heymach J; Fu S; Stephen B; Fok JY; Janku F; Kurzrock R
    Oncotarget; 2013 May; 4(5):772-84. PubMed ID: 23800712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
    Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
    J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
    Goldberg SB; Oxnard GR; Digumarthy S; Muzikansky A; Jackman DM; Lennes IT; Sequist LV
    Oncologist; 2013; 18(11):1214-20. PubMed ID: 24072220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
    Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G
    J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
    Janjigian YY; Azzoli CG; Krug LM; Pereira LK; Rizvi NA; Pietanza MC; Kris MG; Ginsberg MS; Pao W; Miller VA; Riely GJ
    Clin Cancer Res; 2011 Apr; 17(8):2521-7. PubMed ID: 21248303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
    Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
    J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Jackman D; Pao W; Riely GJ; Engelman JA; Kris MG; Jänne PA; Lynch T; Johnson BE; Miller VA
    J Clin Oncol; 2010 Jan; 28(2):357-60. PubMed ID: 19949011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
    Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
    Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
    Oxnard GR; Janjigian YY; Arcila ME; Sima CS; Kass SL; Riely GJ; Pao W; Kris MG; Ladanyi M; Azzoli CG; Miller VA
    Clin Cancer Res; 2011 Oct; 17(19):6322-8. PubMed ID: 21831955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.